Surveillance for Breast Cancer: 73 Real Stories

73 stories match breast cancer and surveillance. 70 of them mention surgery.

Feyama, who was diagnosed with Breast CancerBreast Cancer

HER2-Positive Breast Cancer: Feyama's Survivor Story

Patient Info: Feyama Ashby, Female

Biomarkers: HER2-positive

As of September 2022, Feyama had completed chemotherapy, lumpectomy with lymph-node removal, reconstruction, and 6 weeks of VMAT radiation, and was entering close monitoring for 5 years before survivorship clinic follow-up.

MD Anderson
OutcomeSurvivorship / Surveillance
A patient, who was diagnosed with Invasive Lobular CarcinomaBreast Cancer

Breast cancer with sarcoidosis that mimicked metastatic disease

Patient Info: Anonymized, Female, 40s

Biomarkers: ER-positive; PR-positive; HER2-negative.

Her most recent mammogram showed no recurrent breast cancer while she continued letrozole, goserelin, and six-monthly follow-up.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Invasive Ductal CarcinomaBreast Cancer

HER2-positive left breast cancer treated with trastuzumab and mastectomy

Patient Info: Anonymized, Female, 60s | Stage Metastatic/Advanced

Biomarkers: ER-negative; PR-negative; HER2/CerbB2 strongly positive; BRCA1/2 negative for known pathogenic variants; FANCA variant of uncertain significance.

She remained alive, asymptomatic, and disease-free while undergoing annual surveillance after treatment for the left HER2-positive breast cancer.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Breast CancerBreast Cancer

A BioZorb-Site Density Two Years After Lumpectomy Was Fat Necrosis

Patient Info: Anonymized, Female, 60s

Biomarkers: ER-positive; PR-positive; HER2-negative.

A new density at the lumpectomy site was confirmed as fat necrosis rather than recurrent cancer during ongoing surveillance.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Invasive Ductal CarcinomaBreast Cancer

A New Mass Three Years After Lumpectomy Was Fat Necrosis

Patient Info: Anonymized, Female, 50s

Biomarkers: ER-positive; PR-positive; HER2-negative.

A new mass detected three years after treatment was biopsy-proven fat necrosis rather than recurrent cancer.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Invasive Ductal CarcinomaBreast Cancer

A Mass Beside a BioZorb Implant Was Fat Necrosis, Not Recurrence

Patient Info: Anonymized, Female, 50s

Biomarkers: ER-positive; PR-positive; HER2-negative.

A 1.8 cm mass detected beside the BioZorb site was confirmed as fat necrosis, with continued imaging follow-up recommended.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Invasive Ductal CarcinomaBreast Cancer

Local Breast Cancer Recurrence Was Found During BioZorb Surveillance

Patient Info: Anonymized, Female, 70+

Biomarkers: Initial right breast tumor: ER-positive, PR-positive, HER2-equivocal. Recurrent right breast tumor: ER-positive, HER2-negative.

Two sites of right-breast recurrence were confirmed three years after lumpectomy, leading to right mastectomy.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Breast CancerBreast Cancer

Silicone lymphadenopathy after treatment for recurrent triple-negative breast cancer

Patient Info: Anonymized, Female, 50s

Biomarkers: Triple-negative; BRCA1-negative; BRCA2-negative; latest recurrence Ki-67 60%–70%.

At the May 2020 follow-up, biopsies confirmed silicone-related lymph-node changes rather than cancer, and imaging showed no recurrent disease while six-monthly surveillance continued.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Right breast cancer with contralateral axillary lymph-node metastasis

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Right breast primary: ER-positive; PR-positive; HER2-negative; Ki-67 70%. Left axillary metastasis: ER-positive; PR-negative; HER2-negative; Ki-67 15%; GATA3-positive.

Metastatic Site: contralateral left axillary lymph nodes

Two years after bilateral surgery, clinical and radiological follow-up showed no metastasis or disease recurrence.

PubMed Central
OutcomeCancer-Free / NED
LA
Breast Cancer

Locally advanced male breast cancer associated with a pathogenic ATM variant

Patient Info: Anonymized, Male, 50s | Stage Metastatic/Advanced

Biomarkers: ER 100% positive; PR 100% positive; HER2-negative; Ki-67 30%; germline pathogenic ATM variant c.2921+1G>A.

Two years after diagnosis, he had an ECOG performance status of 0 and remained without signs of breast-cancer relapse or another primary cancer.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage I Invasive Lobular CarcinomaBreast Cancer

Early breast cancer followed 19 years later by a radiation-related breast sarcoma

Patient Info: Anonymized, Female, 70+ | Stage I

Biomarkers: Strongly ER-positive; strongly PR-positive.

The stage IA breast carcinoma remained disease-free for 19 years; a later right-breast mass was a separate radiation-induced sarcoma rather than recurrent carcinoma.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage III Invasive Ductal CarcinomaBreast Cancer

Dramatic chemotherapy response in stage IIIB triple-negative breast cancer

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: ER-negative; PR-negative; HER2-negative; BRCA1-negative; BRCA2-negative; germline FLCN c.1285delC associated with Birt-Hogg-Dubé syndrome; tumor TP53 p.T150fs.

Eighteen months after surgery, she had no recurrence following a dramatic chemotherapy response, bilateral mastectomy, chest-wall radiation, and adjuvant capecitabine.

PubMed Central
OutcomeCancer-Free / NED
Constance, who was diagnosed with Breast CancerBreast Cancer

Breast Cancer: Constance's Survivor Story

Patient Info: Constance Porter, Female

As of January 2020, Constance was cancer-free 3 years after breast cancer diagnosis, while living with permanent hair loss, joint pain from anastrozole, and occasional leg cramps.

MD Anderson
OutcomeCancer-Free / NED
Julie, who was diagnosed with Stage I Invasive Ductal CarcinomaBreast Cancer

Stage I Invasive Ductal Carcinoma: Julie's Patient Story

Patient Info: Julie Martin, Female | Stage I

Julie completed surgery and a five-day proton-radiation course for stage I breast cancer and continued annual mammographic surveillance.

The Patient Story
OutcomeCare Ongoing